Global Markets Direct: Biosimilars and Follow-On Biologics: World Market 2012-2022

Sept. 20, 2012 - PRLog -- Global Markets Direct has added a new report Biosimilars and Follow-On Biologics: World Market 2012-2022 to its market research offerings. What are the commercial prospects for biosimilar drugs? Visiongain's report shows you potential revenues and trends to 2022, discussing data, opportunities and prospects.

This study investigates biosimilars (follow-on biologics). It lets you assess forecasted sales at world market, therapeutic submarket and national level to 2022.
Our investigation gives you business research and analysis with sales forecasts and opinion.

You discover forecasting of six submarkets to 2022, finding potential biosimilar revenues and comparisons with the overall biologics market at category level:
Monoclonal antibodies (MAbs) and fusion proteins
Insulin
Interferons
Erythropoietins
G-CSF agents
Growth hormones.

For more information please click the link below
http://www.globalmarketsdirect.com/Report.aspx?ID=Biosimilars-and-Follow-On-Biologics-World-Market-2012-2022&CompanyID=prlog

The new report gives you coverage of regulatory affairs too - FDA, EMA and others - assessing trends and outlooks for biosimilar drugs.

What will happen next? Our study shows you how biopharmaceutical competition will intensify. The R&D pipeline for follow-on biological drugs is strong and promising. Also, improved drug delivery will be important from 2012. You see how and why.
Patent expiry will erode blockbuster revenues in biopharma, creating many opportunities for biosimilars and related follow-on biologics. More than 20 blockbuster biologics will lose patent protection in the US by 2022.

High demand for more-affordable biological drugs will stimulate the market. We show you sales potentials there. You also see driving and restraining forces in that emerging industry.

What are biopharma companies doing? Our study discusses Sandoz, Teva, Dr. Reddy's, Wockhardt and others, evaluating prospects of the industry and market. You discover where leading companies are heading from 2012.
Many commercial opportunities for biosimilars and related products exist, with high revenues possible to 2022. Product launches will change the market. Our report shows and explains.

You can investigate biosimilar drugs now, discovering revenue potentials and other trends.

This report offers you:

In visiongain's report you find revenue forecasting, growth rates and market shares. Also, you see qualitative analyses (SWOT and STEP) and discussion of R&D activities. You receive 80 tables, 67 charts and four research interviews.

For Table of Contents and Sample Pages please click the link below
http://www.globalmarketsdirect.com/SamplePdfRequest.aspx?...

or

Visit our Report Store

http://www.globalmarketsdirect.com

For more details contact:
pressreleases@globalmarketsdirect.com